JP2018525994A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018525994A5 JP2018525994A5 JP2018510109A JP2018510109A JP2018525994A5 JP 2018525994 A5 JP2018525994 A5 JP 2018525994A5 JP 2018510109 A JP2018510109 A JP 2018510109A JP 2018510109 A JP2018510109 A JP 2018510109A JP 2018525994 A5 JP2018525994 A5 JP 2018525994A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- seq
- sample
- splice variants
- leukemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 23
- 239000000523 sample Substances 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 13
- 101000707567 Homo sapiens Splicing factor 3B subunit 1 Proteins 0.000 claims 10
- 102100031711 Splicing factor 3B subunit 1 Human genes 0.000 claims 10
- 206010009944 Colon cancer Diseases 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000005787 hematologic cancer Diseases 0.000 claims 6
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000001613 neoplastic effect Effects 0.000 claims 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 3
- 206010000871 Acute monocytic leukaemia Diseases 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- 208000017604 Hodgkin disease Diseases 0.000 claims 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 3
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims 3
- 208000034578 Multiple myelomas Diseases 0.000 claims 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 claims 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 3
- 238000001574 biopsy Methods 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000000601 blood cell Anatomy 0.000 claims 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 3
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 210000003734 kidney Anatomy 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 208000014018 liver neoplasm Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 230000003538 neomorphic effect Effects 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 201000000849 skin cancer Diseases 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 206010046766 uterine cancer Diseases 0.000 claims 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims 1
- 238000007901 in situ hybridization Methods 0.000 claims 1
- 238000002493 microarray Methods 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 239000002853 nucleic acid probe Substances 0.000 claims 1
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021074145A JP7256840B2 (ja) | 2015-09-01 | 2021-04-26 | ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562212876P | 2015-09-01 | 2015-09-01 | |
| US62/212,876 | 2015-09-01 | ||
| PCT/US2016/049490 WO2017040526A2 (en) | 2015-09-01 | 2016-08-30 | Splice variants associated with neomorphic sf3b1 mutants |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021074145A Division JP7256840B2 (ja) | 2015-09-01 | 2021-04-26 | ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018525994A JP2018525994A (ja) | 2018-09-13 |
| JP2018525994A5 true JP2018525994A5 (enExample) | 2019-10-10 |
| JP6876680B2 JP6876680B2 (ja) | 2021-05-26 |
Family
ID=56936518
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018510109A Active JP6876680B2 (ja) | 2015-09-01 | 2016-08-30 | ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント |
| JP2021074145A Active JP7256840B2 (ja) | 2015-09-01 | 2021-04-26 | ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021074145A Active JP7256840B2 (ja) | 2015-09-01 | 2021-04-26 | ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10889866B2 (enExample) |
| EP (2) | EP3910073B1 (enExample) |
| JP (2) | JP6876680B2 (enExample) |
| ES (1) | ES2887201T3 (enExample) |
| WO (1) | WO2017040526A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3910073B1 (en) | 2015-09-01 | 2024-03-06 | Eisai R&D Management Co., Ltd. | Splice variants associated with neomorphic sf3b1 mutants |
| SG11201907887SA (en) * | 2017-03-15 | 2019-09-27 | Eisai Co Ltd | Spliceosome mutations and uses thereof |
| US12098172B2 (en) | 2017-07-31 | 2024-09-24 | The Johns Hopkins University | Compositions and methods for targeting MASAs to treat cancers with spliceosome mutations |
| JOP20200243A1 (ar) * | 2018-04-09 | 2020-09-29 | Eisai R&D Man Co Ltd | مركبات البلاديينوليد واستخداماتها |
| IL278740B2 (en) | 2018-06-01 | 2024-01-01 | Eisai R&D Man Co Ltd | Methods for using splicing modulators |
| IL262658A (en) * | 2018-10-28 | 2020-04-30 | Memorial Sloan Kettering Cancer Center | Prevention of age related clonal hematopoiesis and diseases associated therewith |
| JP6931860B2 (ja) * | 2019-02-08 | 2021-09-08 | 株式会社Ｚｅｎｉｃｋ | ｍＲＮＡ前駆体の解析方法、情報処理装置、コンピュータプログラム |
| US20220073971A1 (en) * | 2019-02-08 | 2022-03-10 | Zenick Corporation | Method for analyzing mrna precursor, information processing apparatus, and computer program |
| WO2020264177A1 (en) * | 2019-06-26 | 2020-12-30 | Fred Hutchinson Cancer Research Center | Methods and compositions comprising brd9 activating therapies for treating cancers and related disorders |
| CN111518805A (zh) * | 2020-04-30 | 2020-08-11 | 北京航空航天大学 | 一种可用于抑制肿瘤增殖的非编码基因及其应用 |
| ES2891182A1 (es) * | 2020-07-14 | 2022-01-26 | Servicio Andaluz De Salud | Compuestos para el tratamiento del carcinoma hepatocelular |
| TW202233187A (zh) | 2020-11-04 | 2022-09-01 | 日商衛材R&D企管股份有限公司 | 骨髓發育不良症候群（ｍｄｓ）之生物標記物及其使用方法 |
| CN116507334A (zh) * | 2020-11-04 | 2023-07-28 | 卫材R&D管理有限公司 | 骨髓增生异常综合征（mds）的生物标记物及其使用方法 |
| WO2023131866A1 (en) | 2022-01-05 | 2023-07-13 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
| WO2023209074A1 (en) * | 2022-04-28 | 2023-11-02 | Institut National de la Santé et de la Recherche Médicale | Methods of restoring erythropoiesis in patients suffering from a sf3b1 mutant myelodysplastic syndrome by correcting coasy mis-splicing |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6372431B1 (en) * | 1999-11-19 | 2002-04-16 | Incyte Genomics, Inc. | Mammalian toxicological response markers |
| CN1178973C (zh) | 2000-02-18 | 2004-12-08 | 甘瑟尔股份有限公司 | 官能化聚亚烷基亚胺的制备方法,含有它们的组合物及其应用 |
| US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| TWI312681B (en) | 2001-02-01 | 2009-08-01 | Novel physiologically active substance | |
| US7473767B2 (en) | 2001-07-03 | 2009-01-06 | The Institute For Systems Biology | Methods for detection and quantification of analytes in complex mixtures |
| US20070015271A1 (en) * | 2002-04-04 | 2007-01-18 | Rosen Craig A | Human secreted proteins |
| TWI334866B (en) | 2002-05-29 | 2010-12-21 | Mercian Corp | Novel physiologically active substances |
| US7576204B2 (en) | 2002-07-31 | 2009-08-18 | Mercian Corporation | Heterocyclic macrolide pharmaceutical agent, a method of producing the same and use of the same |
| JP4328293B2 (ja) | 2002-07-31 | 2009-09-09 | メルシャン株式会社 | 新規生理活性物質 |
| EP1580278A4 (en) | 2002-11-29 | 2010-08-25 | Mercian Corp | METHOD FOR PRODUCING A MAKROLIDE COMPOUND |
| KR20060110865A (ko) | 2003-11-27 | 2006-10-25 | 에자이 가부시키가이샤 | 매크로라이드계 화합물의 수산화에 관여하는 ｄｎａ |
| JP4599357B2 (ja) | 2004-07-20 | 2010-12-15 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | プラジエノライドの生合成に関与するポリペプチドをコードするｄｎａ |
| JPWO2007043621A1 (ja) | 2005-10-13 | 2009-04-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | プラジエノライドｂ及びプラジエノライドｄの全合成方法 |
| US20100021918A1 (en) * | 2007-03-05 | 2010-01-28 | Eisai R&D Management Co., Ltd. | Method for assaying action of antitumor agent using splicing defects as index |
| US20080312317A1 (en) | 2007-04-12 | 2008-12-18 | Eisai R&D Management Co., Ltd. | 12 membered-ring macrolactam derivatives |
| ES2614810T3 (es) | 2008-08-14 | 2017-06-02 | Nanostring Technologies, Inc | Nanoindicadores estables |
| WO2011129427A1 (ja) * | 2010-04-16 | 2011-10-20 | 第一三共株式会社 | 癌の診断剤および治療剤 |
| EP2776830B1 (en) | 2011-11-08 | 2018-05-09 | Genomic Health, Inc. | Method of predicting breast cancer prognosis |
| WO2013086464A1 (en) * | 2011-12-07 | 2013-06-13 | The Broad Institute, Inc. | Markers associated with chronic lymphocytic leukemia prognosis and progression |
| JP6057408B2 (ja) | 2012-03-05 | 2017-01-11 | 国立大学法人 千葉大学 | 癌の予防剤および／または治療剤 |
| US20140275010A1 (en) | 2013-03-12 | 2014-09-18 | Guo Zhu Zheng | Quaternary salts |
| WO2014165753A1 (en) | 2013-04-05 | 2014-10-09 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for diagnosis of glioblastoma or a subtype thereof |
| PL3143016T3 (pl) | 2014-05-15 | 2019-04-30 | Eisai R&D Man Co Ltd | Związki i sposoby zastosowania pladienolidu pirydyny |
| EP3910073B1 (en) | 2015-09-01 | 2024-03-06 | Eisai R&D Management Co., Ltd. | Splice variants associated with neomorphic sf3b1 mutants |
-
2016
- 2016-08-30 EP EP21174658.1A patent/EP3910073B1/en active Active
- 2016-08-30 JP JP2018510109A patent/JP6876680B2/ja active Active
- 2016-08-30 ES ES16766420T patent/ES2887201T3/es active Active
- 2016-08-30 US US15/755,225 patent/US10889866B2/en active Active
- 2016-08-30 WO PCT/US2016/049490 patent/WO2017040526A2/en not_active Ceased
- 2016-08-30 EP EP16766420.0A patent/EP3344780B1/en active Active
-
2020
- 2020-11-16 US US17/098,940 patent/US11761045B2/en active Active
-
2021
- 2021-04-26 JP JP2021074145A patent/JP7256840B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018525994A5 (enExample) | ||
| Eyles et al. | Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma | |
| Biankin et al. | Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes | |
| Northcott et al. | Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma | |
| Serrano et al. | Alterations in the p16INK4a/CDKN2A tumor suppressor gene in gastrinomas | |
| Riveiro-Falkenbach et al. | Intra-and inter-tumoral homogeneity of BRAFV600E mutations in melanoma tumors | |
| JP2017512491A5 (enExample) | ||
| JP2015210268A5 (enExample) | ||
| JP7777359B2 (ja) | 融合遺伝子及び／又はエクソンスキッピングにより生ずる転写産物を検出するためのプローブ及び方法 | |
| Bobba et al. | Scar carcinoma of the lung: a historical perspective | |
| JP2019510066A5 (enExample) | ||
| Tsai et al. | Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion | |
| JP2018513679A5 (enExample) | ||
| RU2018145532A (ru) | Композиции и способы диагностирования раковых заболеваний легких с помощью профилей экспрессии генов | |
| ES2947946T3 (es) | Métodos para predecir el riesgo de metástasis en melanoma cutáneo | |
| Matsuura et al. | CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma | |
| Masuda et al. | A case of dedifferentiated solitary fibrous tumor of the thoracic cavity | |
| Andea et al. | Merkel cell carcinoma: correlation of KIT expression with survival and evaluation of KIT gene mutational status | |
| US20190256920A1 (en) | Differential Identification of Pancreatic Cysts | |
| Dimitrakopoulos et al. | Variant of BCL3 gene is strongly associated with five-year survival of non-small-cell lung cancer patients | |
| KR20150132206A (ko) | 예측성 바이오마커에 대한 검정법 | |
| Jelovac et al. | The amplification of c-erb-B2 in cancer-free surgical margins is a predictor of poor outcome in oral squamous cell carcinoma | |
| EP4419668A1 (en) | Use of nanopore sequencing for determining the origin of circulating dna | |
| Shinmura et al. | A novel somatic FGFR3 mutation in primary lung cancer | |
| Huang et al. | Highly sensitive KRAS mutation detection from formalin-fixed paraffin-embedded biopsies and circulating tumour cells using wild-type blocking polymerase chain reaction and Sanger sequencing |